Company Profile

Cellular Dynamics International Inc (AKA: CDI)
Profile last edited on: 11/19/15      CAGE: 474X4      UEI: H1LMMSH2CRJ5

Business Identifier: Stem cell technologies for drug development, cell therapy, tissue engineering and organ regeneration
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

525 Science Drive
Madison, WI 53711
   (608) 310-5100
Location: Single
Congr. District: 02
County: Dane

Public Profile

In March 2015, Cellular Dynamcis was acquired by FujiFilm Holdings and in May ceased trading. Cellular Dynamics International, Inc. (CDI) is developing the next-generation stem cell technologies for drug development and personalized medicine applications. CDI harnesses the power of pluripotent stem cells and their ability to differentiate into any cell type for world-class drug development tools. In addition, it is the leader in iPSC technology, the production of pluripotent stem cell lines from adult tissue. Cellular Dynamics International, Inc. (CDI) is developing stem cell technologies for in vitro drug development, in vivo cellular therapeutics, and stem cell banking. CDI harnesses its unique manufacturing technology to produce differentiated tissue cells in industrial quality, quantity and purity from any individual’s stem cell line created from a standard blood draw. CDI was founded by Dr. James Thomson, a pioneer in human pluripotent stem cell research at the University of Wisconsin-Madison

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2008 2 NIH $499,796
Project Title: Human Embryonic Stem Cell-Derived Cardiomyocytes for In Vitro Drug Screening

Key People / Management

  Robert J Palay -- CEO

  Timothy Daley -- Vice President And Interim Chief Financial Officer

  Jiaqiang He

  Emile Nuwaysir -- Vice President of Research and Development, Manufacturing Quality Systems, Chief

  Thomas M Palay -- President

  Chris Parker -- Vice President and Chief Commercial Officer

  Nicholas Seay -- Vice President and Chief Technology Officer

  James A Thomson -- Chief Scientific Officer